Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 11/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5225148 | 0.86 | MTNR1A (0.52) | MTNR1AMTNR1BNQO2 | |
| SCHEMBL7199704 | 0.84 | MTNR1A (0.43) | MTNR1AMTNR1B | |
| SCHEMBL6075352 | 0.83 | KDM4E (0.35) | MTNR1AMTNR1BCYP1A2 | |
| SCHEMBL7199549 | 0.80 | ALDH1A1 (0.33) | MTNR1ASMN1; SMN2CYP1A2 | |
| SCHEMBL7199002 | 0.77 | MAOB (0.36) | SMN1; SMN2 | |
| SCHEMBL6076322 | 0.75 | MTNR1A (0.32) | MTNR1A | |
| SCHEMBL7203251 | 0.70 | MTNR1A (0.43) | MTNR1AMTNR1BSMN1; SMN2CYP1A2 | |
| SCHEMBL10141758 | 0.65 | APLNR (0.65) | MTNR1AMTNR1B | |
| SCHEMBL4712377 | 0.65 | SMN1; SMN2 (0.60) | MTNR1AMTNR1BSMN1; SMN2CYP1A2 | |
| SCHEMBL19625146 | 0.65 | MTNR1A (0.54) | MTNR1AMTNR1BSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6602903-B2 | Substituted O- and/or S heterocyclic compounds; powerful ligands for melatoninergic receptors. | LES LABORATORIES SERVIER (FR) | 2003-08-05 | — | — | US | disclosed |
| US-20020052400-A1 | Substituted heterocyclic compounds | ADIR ET COMPAGNIE | 2002-05-02 | — | — | US | disclosed |
| US-6313160-B1 | FOR THERAPY AND PROPHYLAXIS OF MELATONINERGIC DISORDERS | ADIR ET COMPAGNIE (FR) | 2001-11-06 | — | — | US | disclosed |
| EP-0998471-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, METHOD FOR PREPARING AND COMPOSITIONS CONTAINING SAME | ADIR ET COMPAGNIE (FR) | 2000-05-10 | — | — | EP | disclosed |
| WO-1998052935-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, METHOD FOR PREPARING AND COMPOSITIONS CONTAINING SAME | ADIR ET COMPAGNIE (FR) | 1998-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052400-A1 | Substituted heterocyclic compounds | MTNR1A, MTNR1B, CBR1 | MTNR1A 1/4885MTNR1B 2/4885SMN1; SMN2 1990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.